NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
BackgroundTo describe demographic, clinical, and neuropsychiatric safety outcomes in a cohort of PD patients treated with LDp/CDp infusion in a real-world setting.MethodsWe retrospectively analyzed a database of 77 consecutive PD patients treated with LDp/CDp at two Italian tertiary referral centers, with a minimum 6-month follow-up. Baseline cognitive, epidemiological, and clinical variables were assessed to determine potential neuropsychiatric adverse event (NAE) risk factors.ResultsPatients had long disease duration (13.8±6.4 years) and moderate-to-severe motor burden (MDS-UPDRS III: 34.4±15). Pre-existing cognitive impairment (MCI 41.6%, dementia 7.8%), prior hallucinations (26%), and impulse control disorders (27.3%) were frequent. At 6 months, mean L-dopa equivalent daily dose increased by ~300 mg (pConclusionsLDp/CDp infusion is well-tolerated. Although NAEs were more frequent than in pivotal trials, they were largely manageable. Frontal executive dysfunction emerged as a significant risk factor, suggesting specific frontal screening should be routine in candidacy evaluation for cognitively frail patients. Preventive strategies to reduce risk are proposed and discussed.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.